Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

Moderate Risk

Score: 45/100

Failure Rate

0.0%

0 terminated/withdrawn out of 4 trials

Success Rate

100.0%

+13.5% vs industry average

Late-Stage Pipeline

0%

0 trials in Phase 3/4

Results Transparency

0%

0 of 1 completed trials have results

Key Signals

Enrollment Performance

Analytics

N/A
3(100.0%)
3Total
N/A(3)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (4)

Showing 4 of 4 trials
NCT07073404Not Yet Recruiting

Omalizumab for Plant-Food Allergy Due to Sensitization to LTP or Profilin

Role: collaborator

NCT03990792Not ApplicableCompleted

Personalized Prevention of Depression in Primary Care

Role: collaborator

NCT04858737Not ApplicableActive Not Recruiting

Personalized Prevention of Depression in the Workplace (e-pD-Work)

Role: collaborator

NCT05682365Not ApplicableUnknown

Online Personalized Intervention for the Prevention of Anxiety.

Role: collaborator

All 4 trials loaded